Pancreatogenic diabetes: special considerations for management

Area of Science:

• Endocrinology
• Oncology
• Gastroenterology

Background:

• Pancreatogenic diabetes (T3cDM) arises from pancreatic disease or resection, presenting unique hormonal and metabolic profiles.
• T3cDM shares similarities with type 1 and type 2 diabetes but has a distinct pathophysiology and a high association with pancreatic cancer.
• Current therapeutic guidelines for T3cDM are lacking despite its distinct clinical features.

Purpose of the Study:

• To review the prevalence, pathophysiology, and cancer associations of T3cDM.
• To evaluate the anti-diabetic and anti-neoplastic roles of metformin in T3cDM.
• To survey the cancer risks associated with other anti-diabetic drugs in the context of T3cDM.

Main Methods:

• Systematic review of published studies on T3cDM prevalence, pathophysiology, and cancer links.
• Analysis of recent research on metformin's protective mechanisms against diabetes and cancer.
• Survey of studies examining the oncogenic potential of alternative anti-diabetic medications.

Main Results:

• T3cDM constitutes 5-10% of diabetes cases in Western populations, often linked to chronic pancreatitis (75%) and increased pancreatic cancer risk.
• Hepatic insulin resistance in T3cDM stems from deficiencies in insulin and pancreatic polypeptide.
• Metformin therapy demonstrates reduced malignancy risk, unlike insulin and insulin secretagogues which may increase it. Pancreatic exocrine insufficiency contributes to malnutrition and bone disease.

Conclusions:

• Glycemic management of T3cDM should prioritize avoiding insulin and secretagogues where feasible.
• Metformin is the recommended first-line treatment for T3cDM, continuing even if insulin is necessary for glucose control.
• Pancreatic enzyme therapy is crucial for managing nutritional deficiencies and metabolic bone disease associated with T3cDM.